Daily Archives: August 14, 2021

France’s First Offshore Substation Preps For Final Journey – Offshore WIND

Posted: August 14, 2021 at 12:46 am

The jacket foundation and the topside of the Saint-Nazaire offshore substation are scheduled to depart from the Nantes Saint-Nazaire Port to the installation site in the coming several days.

The jacket foundation will leave the Nantes Saint-Nazaire Port on Saturday, 14 August.

The topside will follow soon and set off in the evening hours of 17 August, the Nantes Saint-Nazaire Port said.

The four pin piles that will support the jacket foundation were installed at the site by DEME Offshore in April.

Saint-Nazaire, also known as Parc du Banc de Gurande, will comprise 80 GE Haliade 150-6MW turbines and the offshore substation installed between 12 and 20 kilometres off the coast of the Gurande peninsula.

The 480 MW project is scheduled to be operational in the summer of 2022 when it will become the first commercial-scale wind farm installed in French waters.

A consortium of Atlantique Offshore Energy, GE Grid Solutions and Socit de Dragage International (SDI), part of DEME Group,wonthe EPCI contractfor the Saint-Nazaire electrical offshore substation in June 2019.

The wind farm is developed by Eolien Maritime France (EMF), a consortium of EDF Renouvelables, Enbridge, and Canada Pension Plan Investment Board.

Go here to see the original:

France's First Offshore Substation Preps For Final Journey - Offshore WIND

Posted in Offshore | Comments Off on France’s First Offshore Substation Preps For Final Journey – Offshore WIND

US Wind announces developments, expansion in Maryland offshore wind project – MyEasternShoreMD

Posted: at 12:46 am

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Go here to read the rest:

US Wind announces developments, expansion in Maryland offshore wind project - MyEasternShoreMD

Posted in Offshore | Comments Off on US Wind announces developments, expansion in Maryland offshore wind project – MyEasternShoreMD

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast – StreetInsider.com

Posted: at 12:46 am

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

On August 2, 2021, the Dealmaker Podcast posted an interview with Greg McKee, the Chief Executive Officer (CEO) of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF). The show, hosted by Oren Klaff, sought to give the audience an understanding of Tryp Therapeutics operations, along with Mr. McKees personal story on how he ended up as the CEO of the company (https://ibn.fm/Puuse). It offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level.

When discussing what Tryp Therapeutics is all about, Mr. McKee acknowledged the current boom in the psychedelics space and the potential that these substances&

Read More>>

NOTE TO INVESTORS:The latest news and updates relating to TRYPF are available in the companys newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text Groovy to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Read the rest here:

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast - StreetInsider.com

Posted in Psychedelics | Comments Off on Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast – StreetInsider.com

Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights – Business Wire

Posted: at 12:46 am

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, announces the unaudited financial results for the three-month period ended June 30, 2021. A copy of the Companys unaudited interim condensed consolidated financial statements prepared in accordance with International Financial Reporting Standards and the related managements discussion and analysis for the three month period ended June 30, 2021, can be found under the Companys profile on SEDAR at http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov.

Recent Business Highlights:

Doug Drysdale, CEO of Cybin stated, During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space. We believe the molecules we have under development may have the potential to transform the treatment landscape and fill current unmet treatment needs for various psychiatric and neurological conditions. We look forward to sharing updates as we advance our pre-clinical and clinical programs and continue the scientific exploration that we believe will ultimately provide safer and more effective treatments for those suffering with mental illness and addiction issues.

Q1 Financial Highlights

About Cybin

Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and potential treatment regimens for psychiatric disorders.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Companys development of innovative drug delivery systems, the Companys expectations of the molecules under development, the development of Mental Health Centers of Excellence for the purpose of facilitating research and development of innovative psychedelic compound-based therapeutics for patients suffering from depression pursuant to the Collaboration Agreement, and the Companys expectations of its digital therapeutics platform.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three month period ended June 30, 2021, the Companys annual information form for the year ended March 31, 2021, and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov. Although the forward- looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward- looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

The rest is here:

Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights - Business Wire

Posted in Psychedelics | Comments Off on Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights – Business Wire

Orsted 2Q Profit Beats Views; Cautions On Offshore Wind Unit – MarketWatch

Posted: at 12:46 am

By Dominic Chopping

Danish renewable energy company Orsted AS on Thursday posted a higher-than-expected second-quarter net profit and cautioned that it has experienced significantly lower wind speeds than normal, especially across its offshore portfolio.

The company posted a net profit of 5.54 billion Danish kroner ($874.5 million) for the quarter from a loss of DKK1.89 billion a year earlier, as revenue rose 36% to DKK13.55 billion.

A FactSet analysts' forecast had expected net profit of DKK4.78 billion on revenue of DKK14.24 billion.

Orsted backed its full-year guidance still expecting earnings before interest, tax, depreciation and amortization, excluding new partnership agreements, of between DKK15 billion and DKK16 billion.

However, the company said full-year directional guidance for its main offshore unit has changed to significantly lower from lower, mainly due to the significantly lower than normal wind speeds across its entire offshore wind portfolio which has had a DKK1.4 billion impact versus a normal year up until the end of July. Guidance had also been affected by a DKK800 million warranty provision related to the earlier identified issues with cables at some of its wind farms.

The company now expects gross investments in 2021 between DKK39 billion and DKK41 billion from DKK32 billion-DKK34 billion previously.

Write to Dominic Chopping at dominic.chopping@wsj.com

Read more here:

Orsted 2Q Profit Beats Views; Cautions On Offshore Wind Unit - MarketWatch

Posted in Offshore | Comments Off on Orsted 2Q Profit Beats Views; Cautions On Offshore Wind Unit – MarketWatch

Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application – Yahoo Finance

Posted: at 12:46 am

TORONTO, August 12, 2021--(BUSINESS WIRE)--Biomind Labs Inc. ("Biomind Labs" or the "Company") (NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application.

"As we advance in the development of our proprietary line of novel pharmaceuticals, we have filed a new patent application, enabling us to continue building a robust IP strategy. Our focus on our main pillar, fast-acting psychedelics, resides on two tryptamines, N,N-Dimethyltryptamine (DMT) and 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT), two molecules that have the potential to allow us to cross the barrier of 60 minutes on treatments that require a full psychedelic experience. This aligns with our second pillar - affordability. Patients are everything for us, meaning that our novel pharmaceuticals are being developed for all patients that require an alternative medication to traditional anti-depressants, regardless of income level", said Alejandro Antalich, CEO of Biomind Labs.

The patent application filed in the USPTO relates to Biomind Labs proprietary technology on labeled DMT and an associated method for a personalized treatment of neurological and psychiatric disorders. The method monitors DMT levels in relevant body fluids facilitating the design of personalized treatments, regardless of metabolic, genetic, or environmental factors. Further, it is a novel method that allows the development of DMT based treatments available to the modern psychiatric clinical practice.

About Biomind Labs Inc.Biomind is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind is developing novel pharmaceutical formulations of the main natural psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biominds focus is to guarantee patients access to affordable and modern-day treatments and use cases. Biomind understands that long-lasting psychedelic effects make it difficult to create adequate clinical protocols to serve a larger number of patients, and this is the reason why Biomind specializes in fast-acting psychedelics.

Story continues

Cautionary Note Regarding Forward-Looking StatementsThis press release contains statements that constitute "forward-looking information" ("forward-looking information") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Forward-looking statements in this document include, among others, statements relating to building a robust IP strategy, expectations regarding the potential of the Companys products and methods to alleviate certain mental conditions, the business plans and growth plans of the Company, including but not limited to the development of fast relief treatments that require a full psychedelic experience at an affordable price and other statements that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Companys business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Companys securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Companys proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not completed clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Companys performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that managements beliefs, estimates or opinions, or other factors, should change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005045/en/

Contacts

Biomind Labs Inc. Alejandro AntalichChief Executive OfficerEmail: alejandro.antalich@biomindlabs.com

More here:

Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application - Yahoo Finance

Posted in Psychedelics | Comments Off on Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application – Yahoo Finance

rsted sees profits boosted by offshore wind farm stake sale – Windpower Monthly

Posted: at 12:46 am

rsted boosted both its operating profit and net profit in the first half of the year and retained its full-year guidance for 2021.

However, due to issues with cable protection systems and significantly lower wind speeds across its entire offshore wind portfolio, the Danish developer expects full-year Ebitda to be in the lower end of its DKK 15-16 billion (2.01-2.15 billion) guided range.

It recorded Ebitda for the first half of 2021 of DKK 13.1 billion up 34% year on year. This increase was driven by the gain of DKK 5.4 billion after selling a 50% stake in the Dutch offshore wind farm, 752MW Borssele I & II Borssele I & II (752MW) Offshoreoff Zeeland, Netherlands, Europe Click to see full details.

The growth came despite earnings from its operational offshore and onshore wind farms falling 3% to DKK 7.9 billion in the first half of the year. The increased generation capacity from its wind farms was more than offset by significantly lower wind speeds across rsteds portfolio, the developer explained.

It was also hit by several negative impacts in the UK, including higher than expected charges for using the transmission network known asTNUoS tariffs and designed to recover the cost of installing and maintaining the country's transmission system due to rsted boosting its UK wind portfolio; lower earnings from209MW Horns Rev 2 Horns Rev 2 (209MW) Offshoreoff Blvandshuk, Denmark, Europe Click to see full details as a result of the subsidy period ending in October 2020.

rsteds earnings from existing partnerships were also down in the first half of the year. In H1 2020, this figure had been boosted by high earnings from construction agreements related to the1218MW Hornsea Project One Hornsea Project One (1218MW) Offshoreoff Yorkshire, UK, Europe Click to see full details offshore wind farm, while H1 20221 was negatively impacted by a warranty provision related to cable protection system issues at some of its offshore wind farms.

Earnings from bioenergy and other businesses were in line with those from last year.

rsted recorded a net profit of DKK 7.1 billion in the first half of 2021, up from DKK 2.5 billion one year earlier. This was primarily driven by the stake sale in Borssele 1 & 2.

rsted has maintained its full-year Ebitda guidance of DKK 15-16 billion. However, due to wind speeds being significantly lower than normal across its entire offshore wind portfolio and the warranty provisions for cable protection systems, it expects this to be in the lower end of the guided range.

The company has raised its full-year gross investment guidance from DKK 32-34 billion to DKK 39-41 billion, following the completion of a deal to acquire Brookfield Renewables Irelandss onshore wind and solar portfolio in June and due to the expected acquisition of the300MW Lincoln Land Wind Lincoln Land Wind (300MW) OnshoreMorgan County, Illinois, USA, North America Click to see full details project in the US later this year.

More here:

rsted sees profits boosted by offshore wind farm stake sale - Windpower Monthly

Posted in Offshore | Comments Off on rsted sees profits boosted by offshore wind farm stake sale – Windpower Monthly

Pilot Energy to study feasibility of offshore, onshore wind and solar in WA – Renewables Now

Posted: at 12:46 am

August 13 (Renewables Now) - Pilot Energy Limited (ASX:PGY), an Australian junior oil and gas company that aims to become a clean energy developer, will start a feasibility study for its Mid West Wind and Solar Project in Western Australia.

The company aims to use its assets to cornerstone the development of projects potentially including offshore and onshore wind, solar, green and blue hydrogen, carbon capture and storage (CCS) and other infrastructure in the Mid West and South West regions of Western Australia.

The Mid West Wind and Solar Project feasibility study is expected to cost about AUD 900,000 (USD 662,000/EUR 564,000) and Pilot has engaged three consults to conduct it over a period of six months.

The study will look into the integration of offshore and onshore wind and solar projects with existing assets and infrastructure to provide competitive clean energy, Pilot said on Thursday. It will evaluate the renewable energy resources in the Mid West region and their commercialisation via the production and sale of hydrogen, the company explained.

The consultants engaged are Genesis, part of Frances Technip Energies NV (EPA:TE), which will project manage the feasibility study, offshore wind farm development consultant Lautec AU Pty Ltd and renewable energy infrastructure developer Green Fuel Development Pty Ltd (GFD).

Pilot has secured an option to continue with a solar scheme of potentially at least 150 MW currently progressed by GFD.

Lautec, together with C2Wind ApS, will also help Pilot with an offshore wind resource baseline survey that is expected to employ a fixed LiDAR system.

The news follows shareholder approval earlier in August of Pilot's AUD-8 million equity capital raise.

(AUD 1 = USD 0.735/EUR 0.626)

View original post here:

Pilot Energy to study feasibility of offshore, onshore wind and solar in WA - Renewables Now

Posted in Offshore | Comments Off on Pilot Energy to study feasibility of offshore, onshore wind and solar in WA – Renewables Now

W&T Offshore to Participate in Upcoming Investor Conferences – GlobeNewswire

Posted: at 12:46 am

HOUSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE: WTI) (W&T or the Company) today announced that the Company will be participating in two upcoming investor conferences.

The Company will participate in EnerCom, Inc.s The Oil and Gas Conference in Denver, Colorado where Chairman and Chief Executive Officer Tracy W. Krohn is scheduled to make a presentation on Tuesday, August 17th at 4:00 pm Mountain Time. Senior management will also host one-on-one meetings with investors that day. The presentation will be webcast live and archived on W&Ts website, http://www.wtoffshore.com, in the Investors section. An updated investor slide deck will be posted in the Investors section of W&Ts website under Presentations on Tuesday morning, August 17th, 2021.

The Company will also participate in the virtual Seaport Research Partners Annual Summer Investor Conference on Tuesday, August 24th, 2021 by hosting one-on-one meetings with investors and will not be making a formal presentation.

About W&T Offshore

W&T Offshore, Inc. is an independent oil and natural gas producer with operations offshore in the Gulf of Mexico and has grown through acquisitions, exploration and development. The Company currently has working interests in 41 producing fields in federal and state waters and has under lease approximately 622,000 gross acres, including approximately 435,000 gross acres on the Gulf of Mexico Shelf and approximately 187,000 gross acres in the Gulf of Mexico deepwater. A majority of the Companys daily production is derived from wells it operates. For more information on W&T, please visit the Companys website at http://www.wtoffshore.com.

More here:

W&T Offshore to Participate in Upcoming Investor Conferences - GlobeNewswire

Posted in Offshore | Comments Off on W&T Offshore to Participate in Upcoming Investor Conferences – GlobeNewswire

Cruel, costly and ineffective: Australia’s offshore processing asylum seeker policy turns 9 – The Conversation AU

Posted: at 12:46 am

This week marks nine years since Australia re-introduced a policy of offshore processing for asylum seekers arriving by boat. Nine long years of a cruel, costly and ineffective policy sustained by successive governments of both major parties, despite consistently failing to meet any of its stated aims.

As we outline in a new Kaldor Centre policy brief, Cruel, costly and ineffective: the failure of offshore processing in Australia, offshore processing does not save lives, stop the boats or break the business model of people smugglers. Nor is it a benign failure.

Beyond simply not doing what it sets out to do, offshore processing carries enormous costs. There are human costs, for the men, women and children subject to immense suffering, and even to some of the people tasked with implementing it.

It also carries diplomatic costs, as Australias international reputation is tarnished. Its relationship with Pacific neighbours in Nauru and Papua New Guinea grows increasingly strained with each passing year. Then theres the ballooning economic costs for taxpayers, as billions are sunk in vain into a disastrous policy failure.

That no Australian government in almost a decade has successfully brought this policy to a formal close is astonishing, and it demands interrogation.

Read more: With billions more allocated to immigration detention, it's another bleak year for refugees

The governments own data on the impact of offshore processing on boat arrivals is the starkest revelation of this policys failure. During its first year, more people sought asylum in Australia by boat than at any other time since boat arrivals were first recorded in the 1970s. Deaths at sea also continued at broadly comparable rates to previous years.

People continued to seek safety in Australia via maritime routes until they physically could not do so anymore. The 2013 launch of Operation Sovereign Borders, and the Abbott governments commitment to intercepting and returning people trying to reach Australia by boat no matter the legal and humanitarian consequences effectively rendered it futile to try and reach Australia by sea.

Despite early suggestions offshore processing was a vital complement to this turning back of boats, there is no evidence that this is so.

In fact, while offshore processing has formally remained on foot, and popular rhetoric gives the impression that it is still a key part of the matrix of border security measures necessary to keep the boats stopped, Australia ceased transferring new arrivals offshore in 2014.

Instead, Australian officials have gone to extraordinary lengths to intercept at sea and return hundreds of asylum seekers in recent years.

What this means is that transfers offshore occurred for less than two years. The following seven years have been spent in a prolonged and costly policy bind, as successive Labor and Coalition governments have tried to find solutions outside Australia for people who should have been settled here long ago.

Meanwhile almost everyone still subject to this policy is back in Australia, having been either returned following a policy change in July 2013 or medically evacuated amid spiralling health crises offshore from 2017.

According to latest figures, there are barely more than 100 asylum seekers left in each of Nauru and Papua New Guinea. The men and women in Nauru are living in the community. The men in Papua New Guinea are in the capital, Port Moresby, having been transferred there following the closure of the Manus Island detention centre in 2017.

The reason given publicly for continuation of this policy that offshore processing is necessary to prevent a resurgence of boat arrivals has no demonstrated evidentiary basis.

When Australia previously sent asylum seekers offshore, under the Howard government, the majority of people processed offshore and found to be refugees were settled in Australia.

This fact did not prompt an increase in boat arrivals. More recently, there was no spike in boat arrivals when Australia announced that people offshore would be eligible for resettlement in the United States, or when almost everyone was moved back to Australia.

We have just over a thousand asylum seekers here in Australia, and a small number offshore, who have been put through significant trauma in a failed attempt to send a harsh deterrence message to others who might consider trying to reach Australia by boat.

They have been waiting years for a solution, when a simple one is available right now.

All should be permitted to settle permanently in Australia or another appropriate country, provided that alternative is voluntary. Serious consideration should be given to what reparation and rehabilitation Australia may owe the victims of offshore processing.

This deeply flawed policy must not be permitted to reach its ten-year mark.

Read more: Could the Biden administration pressure Australia to adopt more humane refugee policies?

Read more here:

Cruel, costly and ineffective: Australia's offshore processing asylum seeker policy turns 9 - The Conversation AU

Posted in Offshore | Comments Off on Cruel, costly and ineffective: Australia’s offshore processing asylum seeker policy turns 9 – The Conversation AU